Prof. Luis Costa, MD, PhD [7505]
In what types of solid tumors has genomic alteration-directed therapy guided by NGS been shown to improve patient outcomes, including progression-free survival and overall (OS)? (Portuguese)
In what important ways does NGS address the fundamental changes that systemic cancer treatment is undergoing, e.g. moving away from a paradigm in which histopathologically-defined disease is treated primarily with cytotoxic chemotherapy, ...
What common mutations and rearrangements—among them EGFR, ALK, HER2, BRAF, RAS, MET, RET and ROS—present in tumors represent the best molecular targets for cancer therapy? Are some more predictive of success with targeted therapy than others? Why? (Portuguese)
If HER2 rearrangements are documented in breast cancer, what does the NCCN recommend as far as “targeted activity” against this molecular target profile? (Portuguese)
What advantages are derived from a hybridization-capture/NGS approach to comprehensive genomic profiling? And how does NGS help identify therapeutic options when tumors undergo clonal evolution? (Portuguese)